A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody),
either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to
further evaluate its tolerability and efficacy in expansion cohorts once the MTD is
determined.